Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Bria-OTS |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
Bria-OTS comprises a cancer cell line engineered to carry multiple HLA alleles and express a costimulatory molecule (CD80, CD86, or CD40) and immunomodulatory cytokine (GM-CSF, IFNalpha, IL-12, or IL-7), which potentially enhances antitumor immune response (Cancer Res 2023;83(7_Suppl):Abstract nr 685). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bria-OTS | Bria-OTS | 0 | 1 |
| Bria-OTS + Cyclophosphamide + Peginterferon alfa-2b + Tislelizumab | Bria-OTS Cyclophosphamide Peginterferon alfa-2b Tislelizumab | 0 | 1 |